文献速递血栓与止血

N8-GP在经治成人及青少年A型血友病患者中的长期安全性与有效性:pathfinder2最终结果

Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
PubMed 文献 · J Thromb Haemost · 2020-01-01

pathfinder2是一项多国、开放标签试验,纳入186例经治的重型A型血友病青少年及成人患者,接受N8-GP暴露最长6.6年(中位5.4年)。Q4D预防组估算年化出血率为2.14(中位0.84),Q7D预防组为1.31(中位1.67);近30%患者在整个试验期间零出血,止血反应率为83.2%,未发现安全性问题。

要点

  • 186例患者接受N8-GP暴露最长6.6年(中位5.4年),未发现安全性问题。
  • Q4D预防组估算年化出血率2.14(中位0.84),Q7D预防组为1.31(中位1.67)。
  • 近30%患者在整个试验期间零出血,止血反应率83.2%,患者报告结局维持或略有改善。

核心结论

  • 完成的pathfinder2试验数据表明N8-GP在经治青少年及成人重型A型血友病患者中具有疗效和安全性。

研究设计与样本

  • pathfinder2(NCT01480180)是一项多国、开放标签试验,纳入经治的青少年及成人重型A型血友病患者。
  • 扩展期第2部分收集所有方案直至试验结束的长期安全性和有效性数据(首例患者入组主期为2012年1月30日,试验结束为2018年12月10日)。
  • 共186例患者暴露于N8-GP,暴露时间最长6.6年(中位5.4年)。

主要发现

  • Q4D预防组的估算年化出血率为2.14(中位0.84),Q7D预防组的估算年化出血率为1.31(中位1.67)。
  • 近30%的患者在整个试验期间零出血。
  • 所有治疗组的止血反应率为83.2%。
  • 患者报告结局维持或略有改善,未发现安全性问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: N8-GP (turoctocog alfa pegol; Esperoct® , Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated human recombinant factor VIII with a half-life of ~1.6-fold of standard FVIII products. pathfinder2 (NCT01480180) was a multi-national, open-label trial of N8-GP in previously treated adolescent and adult patients with severe hemophilia A. OBJECTIVE: We report end-of-trial efficacy and safety of N8-GP from pathfinder2. METHODS: pathfinder2 main phase and extension phase part 1 results have been previously reported. During extension phase part 2, patients could switch from N8-GP prophylaxis 50 IU/kg every fourth day (Q4D) or 75 IU/kg once weekly (Q7D), depending on bleeding status. Extension phase part 2 collected long-term safety and efficacy data for all regimens until trial end (first patient in main phase, 30 January 2012; trial end, 10 December 2018). RESULTS: Overall, 186 patients were exposed to N8-GP for up to 6.6 years (median 5.4 years). The estimated annualized bleeding rate (ABR) was 2.14 (median 0.84) for the Q4D prophylaxis arm and 1.31 (median 1.67) for the Q7D prophylaxis arm. Nearly 30% of patients experienced zero bleeds throughout the entire duration of the trial, the hemostatic response was 83.2% across all treatment arms, and patient-reported outcomes were maintained or slightly improved. No safety concerns were detected. CONCLUSION: Data from the completed pathfinder2 trial, one of the largest and longest-running clinical trials to investigate treatment of severe hemophilia A, demonstrate the efficacy and safety of N8-GP in previously treated adolescent and adult patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Giangrande P, Abdul Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. J Thromb Haemost. 2020. PMID: 32544297. doi:10.1111/jth.14959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。